A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress

A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress

Receptor tyrosine kinase (RTK), c-Met, is overexpressed and hyper active in renal cell carcinoma (RCC). Most of the therapeutic agents mediate cancer cell death through increased oxidative stress. Induction of c-Met in renal cancer cells promotes the activation of redox-sensitive transcription facto...

Full description

Bibliographic Details
Main Authors: Laxminarayan Rawat, Murugabaskar Balan, Yuzuru Sasamoto, Akash Sabarwal, Soumitro Pal
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Redox Biology
Subjects:
Renal cancer
c-Met
Nrf2
Honokiol
Oxidative stress
Online Access:http://www.sciencedirect.com/science/article/pii/S2213231723003464

Internet

http://www.sciencedirect.com/science/article/pii/S2213231723003464

Similar Items